Within recent years, there has been an increasing interest in purified digitalis preparations. However, in spite of the original optimistic reports, the recent literature tends to discredit the value of the new preparations. Most The first studies recorded are those of the French chemist,Destouches, in 1808, and Quevenue and Homolle, in 1842, who probably already had digitoxin present in their digitaline preparations. In 1868, Nativelle62' 63 isolated from the dried leaves of Digitalis purpurea a relatively pure cardio-active principle, which was given the name of digitaline cristallisee, and was proved to be a potent cardiac drug by Vulpian. It has been marketed in France by the name of digitaline Nativelle. In 1875, the German chemist Schmiedeberg reported70 the isolation of a closely allied material, which he named digitoxin, and stated that it formed the bulk of digitaline cristallisee. Windaus, 85 in 1926, completed the analytical investigation of digitoxin by determining its empirical formula and by interpreting its behavior on hydrolysis.
History
Modern concepts of digitalis therapy began in 1785, with the publication by William Withering of his classical monograph,86 An Account of Foxglove and Some of Its Medical Uses, with Practical Remarks on Dropsy and Other Diseases. Withering, a botanist as well as a physician, recognized that the amount of active material present in the plant was not constant, and he emphasized the importance of controlling the conditions of growth of the plant and the importance of proper selection of the leaves. He cautioned against using the roots because he had observed a great variation in the potency of material obtained from that source. During most of the 19th century Withering's advice was little heeded; purple foxglove was often prescribed indiscriminately and in toxic doses. But the striking clinical results sometimes obtained with such crude preparations stimulated chemists to begin the search for active principles.
The first studies recorded are those of the French chemist,Destouches, in 1808, and Quevenue and Homolle, in 1842, who probably already had digitoxin present in their digitaline preparations. In 1868, Nativelle62' 63 isolated from the dried leaves of Digitalis purpurea a relatively pure cardio-active principle, which was given the name of digitaline cristallisee, and was proved to be a potent cardiac drug by Vulpian. It has been marketed in France by the name of digitaline Nativelle. In 1875, the German chemist Schmiedeberg reported70 the isolation of a closely allied material, which he named digitoxin, and stated that it formed the bulk of digitaline cristallisee. Windaus, 85 in 1926, completed the analytical investigation of digitoxin by determining its empirical formula and by interpreting its behavior on hydrolysis.
Opinions vary about whether or not these two substances are the same. While Weese82 refers to them as identical, Jacobs48 believes that the two products are not exactly the same and states that digitoxin is the chief constituent, probably at least 90 per cent of the original digitaline cristallisee of Nativelle. New and Non-official Remedies uses the names digitaline cristallisee (Nativelle) 87 and a diminished blood volume.11 58 After digitalization, the vital capacity is increased,72' 7 the respiratory minute volume is reduced,9 44 7 and the alveolar carbon dioxide is increased. 71 The basal metabolic rate falls,71' 7 and there is decreased oxygen debt after exercise.65 There is a slowing of the pulse rate in patients with auricular fibrillation and in those cases of congestive failure with a sinus tachycardia. This is brought about both by a vagal stimulation, which may be obliterated by atropine, and by a direct action on the nodal tissues and myocardium, which cannot be obliterated by atropine. Controversy still exists as to the exact mechanism of the action of digitalis. The theory of hepatic vein constriction probably does not apply in man.2' 69 The action of digitoxin is primarily on the myocardium, 1 22, 25, 26, 27, 35 as the effect on the vagus and on the conducting tissue does not account entirely for the beneficial response which may occur before or without a change in rate. Boyer and Poindexter"0 stated that the beneficial effect may be brought about in part by a cortin-like action on the myocardium, whereby potassium is maintained within the cell, and cell hydration is improved.
Therapeutically, the most important use of digitoxin is in congestive heart failure. It is useful regardless of whether the failure is predominantly of the right or left ventricle or both. The etiology of the heart failure modifies the response to the drug. The best results are obtained when failure is due to hypertensive or arteriosclerotic heart disease. Decompensation due to severe rheumatic myocarditis, cardiovascular syphilis, toxic myocarditis, myxedema, hyperthyroidism, and thiamine deficiency is less responsive, if at all. Digitoxin is also indicated in auricular fibrillation and auricular flutter if failure is present. It is not contra-indicated in heart block when failure is present.' " Sometimes it is successful in the treatment of paroxysmal tachycardia."4 87 In coronary thrombosis with failure, it is indicated, but must be carefully regulated, and rapid digitalization is unwise. There is increased sensitivity of the injured myocardium to the drug.3,29 81 Rarely one sees the cerebral symptoms of overdosage such as convulsions, aphasia, and delirium, rather more commonly headache, fatigue, malaise, confusion, drowsiness, and disorientation. Visual disturbances are uncommon, but there may be blurring or disturbances of color vision in which objects appear yellow and green, less frequently blue and red. Amblyopia, scotomata, and diplopia may occur. Sensitivity to digitalis leaf is rarely reported and may be urticarial or scarlatiniform in character, accompanied by an eosinophilia. It has not been reported with digitoxin.
Therefore, whenever digitoxin is used, the appearance of signs of cardiac disorder must be watched for carefully, not only clinically, but with the aid of the electrocardiogram, and such appearance should call for the immediate discontinuance of the drug. Toxic symptoms may persist for a week or more. 18, 55, 77, 84 Clinical use Most patients receiving digitalis continue to require the drug for the remainder of their lives. After digitalization has been attained, the drug must be given daily in order to maintain the beneficial effect. A sufficient amount must be given to replace that which is eliminated and destroyed by the body. Wide variations exist from patient to patient regarding the maintenance dose, and that dose seems to bear no relation to body weight, or to type or severity of heart failure. The rate of excretion varies from day to day and from person to person, depending upon the amount of the drug within the body. It has been shown that the patient does not excrete a fixed amount each day, regardless of the dose given, but, rather, a certain fraction of the amount present in the body. An equilibrium becomes established between the amount of the drug within the body and the rate of elimination. The excretion rate is limited, however, and, with excessive doses, the drug accumulates in the body to a point where toxic symptoms occur. One seeks to give an amount which will restore the highest degree of cardiac efficiency and relieve all symptoms and signs of heart failure, and sometimes this dose borders on the toxic.5' 17, 37, 49 W.W.I Stroud and Vander Veer78 observed that with digitoxin, the digitalizing dose, when given orally over a period of from 3 to 6 days, was between 1.3 to 2.2 mg. The average maintenance dose was 0.1 mg. daily. It was the impression at the Albany Hospital that there were more cases of poisoning from digitoxin than there had been with the wholeleaf preparations. We, therefore, selected 100 cbnsecutive cases which had been adequately digitalized with digitoxin and had been followed for from 3 months to 2 years. Twenty of these cases developed toxic symptoms. They are presented in the accompanying table. As the cases of digitoxin poisoning demonstrate, they do not differ from poisoning with other types of digitalis. The toxic manifestations did persist longer, however, because of the greater cumulative action of the drug. From our experience, it would seem that considerable caution needs to be exercised in the treatment of patients with congestive heart failure with the digitoxin preparations. Purified glycosides will not result in more efficient or safer digitalization if administered haphazardly.
As has been pointed out by DeGraff, Batterman, and Rose,18 the response of a patient to digitalis depends upon the degree of congestive failure, the theoretical maximum improvement possible, depending upon the underlying heart disease, and the precipitating cause of heart failure. The necessary for digitalization permits administration of a large fraction in a single dose, with only a small incidence of local gastro-intestinal irritation. The rapid onset of action produces quick digitalization by the oral route so that intravenous administration is rarely necessary. There is some evidence that various preparations of digitoxin differ in potency; therefore, as with the whole-leaf digitalis, it is advisable for physicians to use a single preparation with whose action and potency they are familiar. The cost of digitoxin is no longer appreciably greater than that of the whole-leaf digitalis. However, the variability in response to fixed amounts of the drug and the relatively high incidence of toxicity to the generally accepted maintenance dose impose marked limitations on its use. It is probably not the drug of choice for routine digitalization.
Summary and conclusions 1. The history, pharmacology, and toxicity of digitoxin are briefly presented.
2. In a follow-up study of from 3 months to 2 years of 100 consecutive patients in congestive heart failure treated with digitoxin, we have observed toxic symptoms in 20 per cent of the cases. Twenty cases of toxicity are presented briefly.
3. The toxic symptoms appear more frequently with digitoxin than with whole-leaf digitalis, and the toxic manifestations are more prolonged.
4. In most patients 1.2 mg. of digitoxin given in the first 24 hours are not sufficient to achieve adequate digitalization. With 
